Lehmann J - Search Results

1

Evaluation of Homobivalent Carbolines as Designed Multiple Ligands for the Treatment of Neurodegenerative Disorders.

Otto R, Penzis R, Gaube F, Adolph O, Föhr KJ, Warncke P, Robaa D, Appenroth D, Fleck C, Enzensperger C, Lehmann J, Winckler T. Otto R, et al. Among authors: lehmann j. J Med Chem. 2015 Aug 27;58(16):6710-5. doi: 10.1021/acs.jmedchem.5b00958. Epub 2015 Aug 17. J Med Chem. 2015. PMID: 26278660

2

Bivalent beta-carbolines as potential multitarget anti-Alzheimer agents.

Rook Y, Schmidtke KU, Gaube F, Schepmann D, Wünsch B, Heilmann J, Lehmann J, Winckler T. Rook Y, et al. Among authors: lehmann j. J Med Chem. 2010 May 13;53(9):3611-7. doi: 10.1021/jm1000024. J Med Chem. 2010. PMID: 20361801

3

Beta and gamma carboline derivatives as potential anti-Alzheimer agents: A comparison.

Otto R, Penzis R, Gaube F, Winckler T, Appenroth D, Fleck C, Tränkle C, Lehmann J, Enzensperger C. Otto R, et al. Among authors: lehmann j. Eur J Med Chem. 2014 Nov 24;87:63-70. doi: 10.1016/j.ejmech.2014.09.048. Epub 2014 Sep 16. Eur J Med Chem. 2014. PMID: 25240096

4

Dopamine/serotonin receptor ligands. 13: Homologization of a benzindoloazecine-type dopamine receptor antagonist modulates the affinities for dopamine D(1)-D(5) receptors.

Enzensperger C, Lehmann J. Enzensperger C, et al. Among authors: lehmann j. J Med Chem. 2006 Oct 19;49(21):6408-11. doi: 10.1021/jm060213k. J Med Chem. 2006. PMID: 17034146

5

Dopamine/serotonin receptor ligands. Part 17: a cross-target SAR approach: affinities of azecine-styled ligands for 5-HT(2A) versus D1 and D2 receptors.

Enzensperger C, Görnemann T, Pertz HH, Lehmann J. Enzensperger C, et al. Among authors: lehmann j. Bioorg Med Chem Lett. 2008 Jul 1;18(13):3809-13. doi: 10.1016/j.bmcl.2008.04.081. Epub 2008 May 6. Bioorg Med Chem Lett. 2008. PMID: 18534847

6

NO-donating tacrine hybrid compounds improve scopolamine-induced cognition impairment and show less hepatotoxicity.

Fang L, Appenroth D, Decker M, Kiehntopf M, Lupp A, Peng S, Fleck C, Zhang Y, Lehmann J. Fang L, et al. Among authors: lehmann j. J Med Chem. 2008 Dec 25;51(24):7666-9. doi: 10.1021/jm801131a. J Med Chem. 2008. PMID: 19053746

7

Dibenzazecine scaffold rebuilding--is the flexibility always essential for high dopamine receptor affinities?

Schulze M, Müller FK, Mason JM, Görls H, Lehmann J, Enzensperger C. Schulze M, et al. Among authors: lehmann j. Bioorg Med Chem. 2009 Oct 1;17(19):6898-907. doi: 10.1016/j.bmc.2009.08.028. Epub 2009 Aug 20. Bioorg Med Chem. 2009. PMID: 19744859

8

Dopamine receptor ligands. Part 18: (1) modification of the structural skeleton of indolobenzazecine-type dopamine receptor antagonists.

Robaa D, Enzensperger C, Abul Azm Sel D, El Khawass el S, El Sayed O, Lehmann J. Robaa D, et al. Among authors: lehmann j. J Med Chem. 2010 Mar 25;53(6):2646-50. doi: 10.1021/jm901291r. J Med Chem. 2010. PMID: 20180564

9

A novel non-phenolic dibenzazecine derivative with nanomolar affinities for dopamine receptors.

Robaa D, Eldin AbulAzm S, Lehmann J, Enzensperger C. Robaa D, et al. Among authors: lehmann j. Chem Biodivers. 2011 Mar;8(3):431-9. doi: 10.1002/cbdv.201000317. Chem Biodivers. 2011. PMID: 21404426

10

Chiral indolo[3,2-f][3]benzazecine-type dopamine receptor antagonists: synthesis and activity of racemic and enantiopure derivatives.

Robaa D, Enzensperger C, Eldin Abulazm S, Hefnawy MM, El-Subbagh HI, Wani TA, Lehmann J. Robaa D, et al. Among authors: lehmann j. J Med Chem. 2011 Oct 27;54(20):7422-6. doi: 10.1021/jm200676f. Epub 2011 Sep 29. J Med Chem. 2011. PMID: 21888437

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,503 results

Search Page

Filters